Alnylam Pharmaceuticals Inc. (ALNY)

75.37
NASDAQ : Health Technology
Prev Close 75.89
Day Low/High 74.75 / 75.95
52 Wk Low/High 60.27 / 124.22
Avg Volume 928.50K
Exchange NASDAQ
Shares Outstanding 110.98M
Market Cap 8.42B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Alnylam Submits Clinical Trial Authorization (CTA) Application For ALN-AAT02, An Investigational RNAi Therapeutic For The Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)

Alnylam Submits Clinical Trial Authorization (CTA) Application For ALN-AAT02, An Investigational RNAi Therapeutic For The Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has submitted an Clinical Trial Authorization (CTA) application to the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a...

Alnylam Launches ONPATTRO™ (patisiran), The First-Ever RNAi Therapeutic, In Germany

Alnylam Launches ONPATTRO™ (patisiran), The First-Ever RNAi Therapeutic, In Germany

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that ONPATTRO (patisiran) is now available in Germany.

Alnylam Reports New Platform Innovations For RNAi Therapeutics At The Oligonucleotide Therapeutics Society 2018 Annual Meeting

Alnylam Reports New Platform Innovations For RNAi Therapeutics At The Oligonucleotide Therapeutics Society 2018 Annual Meeting

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today further progress on the Company's platform efforts in extrahepatic delivery of novel siRNA conjugates, including central nervous system (CNS) and ocular...

Alnylam Announces Submission Of New Drug Application In Japan For ONPATTRO™ (patisiran Sodium) For Treatment Of Hereditary ATTR Amyloidosis

Alnylam Announces Submission Of New Drug Application In Japan For ONPATTRO™ (patisiran Sodium) For Treatment Of Hereditary ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has submitted a New Drug Application (NDA) to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for approval of patisiran for the...

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Alnylam Pharmaceuticals, Inc. Investors (ALNY)

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Alnylam Pharmaceuticals, Inc. Investors (ALNY)

Law Offices of Howard G. Smith announces an investigation on behalf of Alnylam Pharmaceuticals, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. - ALNY

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. - ALNY

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Alnylam Pharmaceuticals, Inc.

Alnylam Announces Positive Topline Results From Interim Analysis Of ENVISION Phase 3 Study Of Givosiran In Patients With Acute Hepatic Porphyria

Alnylam Announces Positive Topline Results From Interim Analysis Of ENVISION Phase 3 Study Of Givosiran In Patients With Acute Hepatic Porphyria

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive topline results from the interim analysis of the ENVISION Phase 3 Study of givosiran, an investigational RNAi therapeutic targeting...

Alnylam To Webcast Presentation At The 2018 Cantor Global Healthcare Conference

Alnylam To Webcast Presentation At The 2018 Cantor Global Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 2018 Cantor Global Healthcare Conference on Wednesday, October 3, 2018 at 9:45 am ET at the...

Alnylam Announces Publication In Circulation Of Exploratory Cardiac Endpoint Data From APOLLO Phase 3 Study Of Patisiran

Alnylam Announces Publication In Circulation Of Exploratory Cardiac Endpoint Data From APOLLO Phase 3 Study Of Patisiran

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today publication of data from exploratory cardiac assessments in the APOLLO Phase 3 study of patisiran, an RNAi therapeutic for the treatment of the...

Alnylam Receives Approval Of ONPATTRO™ (patisiran) In Europe

Alnylam Receives Approval Of ONPATTRO™ (patisiran) In Europe

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the European Commission (EC) has granted marketing authorization for ONPATTRO ™ (patisiran) for the treatment of hereditary transthyretin-mediated...

Alnylam To Webcast Presentations At Upcoming September Investor Conferences

Alnylam To Webcast Presentations At Upcoming September Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 2018 Wells Fargo Securities Healthcare Conference on Wednesday, September 5,...

Alnylam Completes Enrollment In ENVISION Phase 3 Study Of Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias (AHPs)

Alnylam Completes Enrollment In ENVISION Phase 3 Study Of Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias (AHPs)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has achieved full patient accrual in its ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid...

Alnylam Announces Alignment On Value-Based Agreements With Leading Health Insurers And Launches Comprehensive Patient Support Services For ONPATTRO™ (patisiran)

Alnylam Announces Alignment On Value-Based Agreements With Leading Health Insurers And Launches Comprehensive Patient Support Services For ONPATTRO™ (patisiran)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has agreed on the structure and key terms of value-based agreements (VBA) with leading health insurers for ONPATTRO™ (patisiran) lipid complex...

ONPATTRO™ (patisiran) Packaging And Product Vial (Photo: Business Wire)

ONPATTRO™ (patisiran) Packaging And Product Vial (Photo: Business Wire)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration (FDA) approved ONPATTRO™ (patisiran) lipid complex injection, a first-of-its-kind RNA interference...

Alnylam Announces That The United Kingdom's MHRA Grants Early Access To Patisiran

Alnylam Announces That The United Kingdom's MHRA Grants Early Access To Patisiran

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has granted patisiran, an investigational RNAi therapeutic in development for the...

Alnylam Pharmaceuticals Reports Second Quarter 2018 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports Second Quarter 2018 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2018 and highlighted recent progress in advancing its pipeline.

Alnylam To Webcast Conference Call Discussing Second Quarter 2018 Financial Results

Alnylam To Webcast Conference Call Discussing Second Quarter 2018 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2018 on Thursday, August 2, 2018, before the U.

Alnylam Receives Positive CHMP Opinion For ONPATTRO™ (patisiran) For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults With Stage 1 Or Stage 2 Polyneuropathy

Alnylam Receives Positive CHMP Opinion For ONPATTRO™ (patisiran) For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults With Stage 1 Or Stage 2 Polyneuropathy

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a Positive Opinion recommending marketing authorization of patisiran for the...

Alnylam Presents New Analyses Of Clinical Results From APOLLO Phase 3 Study Of Patisiran At 2018 Peripheral Nerve Society Annual Meeting

Alnylam Presents New Analyses Of Clinical Results From APOLLO Phase 3 Study Of Patisiran At 2018 Peripheral Nerve Society Annual Meeting

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the Company presented new analyses from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary...

Alnylam Announces Publication Of APOLLO Phase 3 Clinical Study Results For Investigational RNAi Therapeutic Patisiran In The New England Journal Of Medicine

Alnylam Announces Publication Of APOLLO Phase 3 Clinical Study Results For Investigational RNAi Therapeutic Patisiran In The New England Journal Of Medicine

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the pivotal study results from the APOLLO Phase 3 trial of patisiran were published online today in The New England Journal of Medicine (NEJM).

Alnylam To Host Fifth Annual "RNAi Roundtable" Webcast Series

Alnylam To Host Fifth Annual "RNAi Roundtable" Webcast Series

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 5 th annual series of "RNAi Roundtable" webcasts this summer.

Alnylam Expands Senior Leadership Team With Two Key Appointments

Alnylam Expands Senior Leadership Team With Two Key Appointments

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointments of two accomplished biotech executives, Masako Nakamura as Senior Vice President, Head of Asia, and Jing L.

Alnylam To Report New Clinical Results For Patisiran At The 4th Congress Of The European Academy Of Neurology

Alnylam To Report New Clinical Results For Patisiran At The 4th Congress Of The European Academy Of Neurology

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR)...

Over 700 Alnylam Employees Volunteer At The Company's 4th Annual "Helping Hands" Community Service Day

Over 700 Alnylam Employees Volunteer At The Company's 4th Annual "Helping Hands" Community Service Day

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today kicked off its fourth annual company-wide "Helping Hands" Community Service Day benefiting 23 organizations, including 16 organizations in the Greater Boston area...

Alnylam Reports Updated Positive Results From Phase 1/2 Study Of Lumasiran In Patients With Primary Hyperoxaluria Type 1 (PH1)

Alnylam Reports Updated Positive Results From Phase 1/2 Study Of Lumasiran In Patients With Primary Hyperoxaluria Type 1 (PH1)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase (GO) for the treatment of...

Alnylam Receives Orphan Drug Designation From The United States Food & Drug Administration For ALN-TTRsc02, A Subcutaneously Delivered Investigational RNAi Therapeutic For The Treatment Of Transthyretin-Mediated Amyloidosis

Alnylam Receives Orphan Drug Designation From The United States Food & Drug Administration For ALN-TTRsc02, A Subcutaneously Delivered Investigational RNAi Therapeutic For The Treatment Of Transthyretin-Mediated Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to ALN-TTRsc02, an investigational RNAi therapeutic for the...

Alnylam To Webcast Presentations At Upcoming June Investor Conferences

Alnylam To Webcast Presentations At Upcoming June Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Bernstein 34 th Annual Strategic Decisions Conference on Friday, June 1, 2018...

Alnylam Appoints Colleen Reitan To The Board Of Directors

Alnylam Appoints Colleen Reitan To The Board Of Directors

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of a veteran healthcare leader, Colleen Reitan, to Alnylam's Board of Directors, effective June 1, 2018.

Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery Of RNAi Therapeutics

Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery Of RNAi Therapeutics

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has achieved delivery of novel small interfering RNA (siRNA) conjugates to the central nervous system (CNS) and is planning to advance a...

Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2018 and highlighted recent progress in advancing its pipeline.